An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
After buying two CMOs, Japanese glassmaker AGC has made “a full-fledged launch” into the biologics manufacturing space and says it will consider further M&A opportunities.
DSM Pharmaceutical Products (DPP) has won its second biologics manufacturing contract in two months signing up Brazil’s Recepta Biopharma as a new customer.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
Cambridge Consultants (CC) says experience developing auto-injector technologies was critical to its contract appraisal work during Consort Medical’s £16.8m (€11.5m) takeover of The Medical House (TMH).
Tablet-coating specialist BioProgress formalised its agreement with
US chemicals and machinery group FMC in deal that could be worth up
to $160 million (€128m) in revenues in the first six years.
